This Phase I clinical study evaluates a single dose of 186RNL (radionuclide clinical study drug) administered through an intraventricular catheter (Ommaya reservoir) in participants with Leptomeningeal Metastases (LM).~The clinical study treatment consists of a single administered 5cc dose of 186RNL per participant.~The clinical study will include the evaluation of three separate dose levels. Three to six participants may be treated at each dose.~The maximum number of participants to be enrolled in the study is 18.~The clinical study treatment will be administered, following a CSF flow study, on an outpatient basis by the clinical study physician.~Participants will be followed for up to 12 months after the clinical study drug is administered.~The U.S. Food and Drug Administration (FDA) has not approved 186RNL for this specific disease.
This is an open-label Phase I clinical study that will administer a single dose of 186RNL via intraventricular catheter for treatment of Leptomeningeal Metastases (LM).